Mounjaro 15mg Injection contains Tirzepatide, a once-weekly injectable medicine approved for the treatment of type 2 diabetes. It works by activating GIP and GLP-1 receptors, helping to lower blood sugar, improve insulin sensitivity, reduce appetite, and support weight loss. This is the highest strength available, usually prescribed to patients who have been gradually titrated from lower doses (2.5mg up to 12.5mg) for optimal blood sugar control and weight management.
Uses:
Improves glycemic control in adults with type 2 diabetes.
Helps with weight management in overweight or obese individuals.
May reduce risk of heart attack, stroke, and cardiovascular events in diabetic patients.
Used alongside diet and exercise, with or without other antidiabetic medicines.
Dosage:
Administered once weekly as a subcutaneous injection (abdomen, thigh, or upper arm).
Usual dose: 15mg once weekly, only after proper dose escalation.
Do not inject into the same site consecutively.
Strictly follow the doctor’s instructions.
Side Effects:
Common: nausea, vomiting, diarrhea, reduced appetite, constipation.
Moderate: abdominal pain, indigestion, fatigue.
Serious (rare): pancreatitis, hypoglycemia (especially if combined with insulin), allergic reactions, thyroid tumors (seen in animal studies).
Precautions:
Not indicated for type 1 diabetes or diabetic ketoacidosis.
Avoid if there is a personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome.
Regularly monitor blood sugar and weight during treatment.
Not recommended during pregnancy or breastfeeding.
